Cupid Ltd (NSE: CUPID) Shares Jump +5.23% to ₹207.28 Amid Strong Buying Interest

Cupid Ltd shares jumped 5.23% to ₹207.28 on July 9, 2026, extending a powerful multi-day rally. The stock closed the previous session at ₹196.98 before today’s fresh buying momentum. Heavy volumes accompanied the move, reflecting sustained investor confidence in the condom and diagnostics maker. This surge follows Wednesday’s 2% gain after Cupid raised its FY27 revenue guidance sharply. Cupid Ltd shares have now rallied nearly 940% over the past twelve months. Here’s what’s fueling this latest leg of the rally.

Why Cupid Ltd Shares Are Rising Today

Cupid Ltd (CUPID.NS) built on Wednesday’s gains, adding another 5.23% to close near ₹207.28. The company expects record June-quarter revenue exceeding ₹150 crore for Q1FY27. Management also raised full-year FY27 revenue guidance to more than ₹660 crore.

• Today’s gain: 5.23%, closing near ₹207.28
• Previous close: ₹196.98 on July 8, 2026
• Q1FY27 revenue guidance: more than ₹150 crore
• FY27 full-year revenue guidance: more than ₹660 crore

Strong execution across sexual wellness, exports, and diagnostics segments drove this confident guidance. Investors responded by pushing Cupid Ltd shares to fresh multi-week highs today.

A Look At Cupid’s Recent Financial Track Record

Cupid Ltd’s FY26 net profit rose 164.69% year-on-year to ₹108.23 crore. Full-year sales grew 94.92% to ₹357.71 crore, reflecting broad-based demand strength. Q4FY26 alone saw net profit jump 215.03% year-on-year to ₹36.26 crore.

• FY26 net profit: ₹108.23 crore, up 164.69% YoY
• FY26 sales: ₹357.71 crore, up 94.92% YoY
• Q4FY26 net profit: ₹36.26 crore, up 215.03% YoY
• Q3FY26 EBITDA margin: 37%, up from 25% a year earlier

This consistent earnings acceleration explains why Cupid Ltd commands such strong market attention today. Investors increasingly view the company as a structural growth story, not a one-quarter surprise.

What’s Driving Cupid’s Long-Term Growth Story

Cupid Ltd supplies condoms globally under a five-year South Africa National Condom Programme running through 2030. That contract carries an annual allocation value near $12.98 million, roughly ₹115 crore. The company ships about 23.4 million female condoms and 153 million male condoms yearly under this deal.

• South Africa contract value: approximately $12.98 million annually
• Annual female condom supply: 23.4 million units
• Annual male condom supply: 153 million units
• Key export markets: Tanzania, Brazil, Kenya, Ethiopia, Philippines, EU, Middle East

This diversified export base reduces Cupid Ltd’s reliance on any single geography or buyer. Management continues expanding into new regions, supporting long-term revenue visibility beyond FY27.

Diagnostics Business Adds A Second Growth Engine

Cupid Ltd’s diagnostics division now produces 15 rapid IVD test kits, including HIV and pregnancy tests. Three additional test kits remain under active development within the company’s diagnostics pipeline. Current manufacturing capacity stands at over 150,000 kits daily, targeting 400,000 kits eventually.

This diagnostics expansion positions Cupid Ltd alongside listed peers like Thyrocare Technologies in India’s testing space. The segment diversifies Cupid Ltd’s revenue base beyond its traditional condom manufacturing business significantly.

Corporate Actions Adding To Investor Interest

Cupid Ltd’s board approved a 4:1 bonus share issuance, pending shareholder and regulatory approvals. The company also invested ₹82.88 crore into Baazar Style Retail Limited, part of a planned ₹331.53 crore commitment. These corporate actions have added further speculative interest around Cupid Ltd shares recently.

• Bonus issue ratio: 4 shares for every 1 held
• Baazar Style Retail investment: ₹82.88 crore of ₹331.53 crore planned
• Investment structure: 1.01 crore convertible warrants, 25% paid upfront

Final Thoughts

Cupid Ltd’s 5.23% jump to ₹207.28 reflects genuine operational momentum, not just speculative trading. Raised FY27 guidance, strong diagnostics growth, and export contract wins all support today’s rally. With shares up nearly 940% over the past year, valuation discipline matters going forward. Investors tracking Cupid Ltd alongside diagnostics peers like Thyrocare Technologies should watch upcoming Q1FY27 results closely.

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice